Carswell EA, Old LJ, Kassel R, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci. 1975;72(9):3666–70.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science. 1985;229(4716):869–71.

Article  CAS  PubMed  Google Scholar 

Tracey KJ, Lowry SF, Fahey TJ, et al. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog. Surg Gynecol Obstet. 1987;164(5):415–22.

CAS  PubMed  Google Scholar 

Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. The Lancet. 1987;329(8529):355–7.

Article  Google Scholar 

Suffredini AF, Fromm RE, Parker MM, et al. The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med. 1989;321(5):280–7.

Article  CAS  PubMed  Google Scholar 

da Silva AMT, Kaulbach HC, Chuidian FS, Lambert DR, Suffredini AF, Danner RL. Shock and multiple-organ dysfunction after self-administration of salmonella endotoxin. N Engl J Med. 1993;328(20):1457–60.

Article  Google Scholar 

Abraham E. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA. 1997;277(19):1531.

Article  CAS  PubMed  Google Scholar 

Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group Lancet. 1998;351(9107):929–33.

Article  CAS  Google Scholar 

Reinhart K, Menges T, Gardlund B, et al. Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: the RAMSES study. Crit Care Med. 2001;29(4):765–9.

Article  CAS  PubMed  Google Scholar 

Gallagher J, Fisher C, Sherman B, et al. A multicenter, open-label, prospective, randomized, dose-ranging pharmacokinetic study of the anti-TNF-α antibody afelimomab in patients with sepsis syndrome. Intensiv Care Med. 2001;27(7):1169–78.

Article  CAS  Google Scholar 

Fisher CJ, Agosti JM, Opal SM, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. N Engl J Med. 1996;334(26):1697–702.

Article  CAS  PubMed  Google Scholar 

Urbaschek R, Urbaschek B. Tumor necrosis factor and interleukin 1 as mediators of endotoxin-induced beneficial effects. Clin Infect Dis. 1987;9(5):S607–15.

Article  CAS  Google Scholar 

Havell EA. Production of tumor necrosis factor during murine listeriosis. J Immunol. 1987;139(12):4225–31.

Article  CAS  PubMed  Google Scholar 

Chaudhry H, Zhou J, Zhong Y, Ali MM, Nagarkatti PS, Nagarkatti M. Role of Cytokines as a Double-edged Sword in Sepsis. 2015;28.

Cavaillon JM. Pro-versus anti-inflammatory cytokines: myth or reality. Cell Mol Bio. 2001;47(4):695–702.

CAS  Google Scholar 

Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349(1):g7647–g7647.

Article  Google Scholar 

Deeks J, Higgins J, Altman D (editors). Chapter 10: Analysing data and undertaking meta-analyses [Internet]. In: Cochrane Handbook for Systematic Reviews of Interventions version 6.4. 2023. Available from: https://training.cochrane.org/handbook/current/chapter-10

Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA. 2016;315(8):801.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014;14(1):43.

Article  PubMed  PubMed Central  Google Scholar 

Kim JH. Multicollinearity and misleading statistical results. Korean J Anesthesiol. 2019;72(6):558–69.

Article  PubMed  PubMed Central  Google Scholar 

Echtenacher B, Urbaschek R, Weigl K, Freudenberg MA, Männel DN. Treatment of experimental sepsis-induced immunoparalysis with TNF. Immunobiology. 2003;208(4):381–9.

Article  CAS  PubMed  Google Scholar 

Perrone LA, Szretter KJ, Katz JM, Mizgerd JP, Tumpey TM. Mice lacking both TNF and IL-1 receptors exhibit reduced lung inflammation and delay in onset of death following infection with a highly virulent H5N1 virus. J Infect Dis. 2010;202(8):1161–70.

Article  CAS  PubMed  Google Scholar 

Belisle SE, Tisoncik JR, Korth MJ, et al. Genomic profiling of tumor necrosis factor alpha (TNF-α) receptor and interleukin-1 receptor knockout mice reveals a link between TNF-α signaling and increased severity of 1918 pandemic influenza virus infection. J Virol. 2010;84(24):12576–88.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Peper RL, Van Campen H. Tumor necrosis factor as a mediator of inflammation in influenza A viral pneumonia. Microb Pathog. 1995;19(3):175–83.

Article  CAS  PubMed  Google Scholar 

Shi X, Zhou W, Huang H, et al. Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice. Crit Care. 2013;17(6):R301.

Article  PubMed  PubMed Central  Google Scholar 

Branche E., Tang W.W., Viramontes K.M., et al. Synergism between the tyrosine kinase inhibitor sunitinib and Anti-TNF antibody protects against lethal dengue infection. Antiviral Research 2018;158((Shresta S., sujan@lji.org) Department of Medicine, School of Medicine, University of California, La Jolla, San Diego, CA, United States):1–7.

Phanthanawiboon S, Limkittikul K, Sakai Y, Takakura N, Saijo M, Kurosu T. Acute systemic infection with dengue virus leads to vascular leakage and death through tumor necrosis factor-α and Tie2/angiopoietin signaling in mice lacking type I and II interferon receptors. PLoS ONE. 2016;11(2): e0148564.

Article  PubMed  PubMed Central  Google Scholar 

Atrasheuskaya A, Petzelbauer P, Fredeking TM, Ignatyev G. Anti-TNF antibody treatment reduces mortality in experimental dengue virus infection. FEMS Immunol Med Microbiol. 2003;35(1):33–42.

Article  CAS  PubMed  Google Scholar 

Doherty PC, Allan JE, Clark IA. Tumor necrosis factor inhibits the development of viral meningitis or induces rapid death depending on the severity of inflammation at time of administration. J Immunol. 1989;142(10):3576–80.

Article  CAS  PubMed  Google Scholar 

Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor alpha/cachectin and murine interleukin 1 alpha protects mice from lethal bacterial infection. J Exp Med. 1989;169(6):2021–7.

Article  CAS  PubMed  Google Scholar 

Echtenacher B, Falk W, Mannel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol. 1990;145(11):3762–6.

Article  CAS  PubMed  Google Scholar 

Dharmana E, Keuter M, Netea MG, Verschueren ICMM, Kullberg BJ. Divergent effects of tumor necrosis factor-α and lymphotoxin-α on lethal endotoxemia and infection with live Salmonella typhimurium in mice. Eur Cytokine Netw. 2002;13(1):104–9.

CAS  PubMed  Google Scholar 

Rothe J, Lesslauer W, Lötscher H, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature. 1993;364(6440):798–802.

Article  CAS  PubMed  Google Scholar 

Pfeffer K, Matsuyama T, Kündig TM, et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell. 1993;73(3):457–67.

Article  CAS  PubMed